Inovio receives regulatory authorization to conduct phase 3 efficacy trial of its covid-19 dna vaccine candidate, ino-4800, in mexico

Plymouth meeting, pa., sept. 22, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced that it has received authorization from cofepris (comisiÓn federal para la protecciÓn contra riesgos sanitarios), the national health regulatory agency of mexico, to conduct a clinical trial in that country as part of the phase 3 segment of inovio's global phase 2/3 trial, innovate ( in ovio i no -4800 va ccine t rial for e fficacy), for its dna vaccine candidate for covid-19, ino-4800.
INO Ratings Summary
INO Quant Ranking